Chemistry: molecular biology and microbiology – Vector – per se
Patent
1998-01-16
2000-06-27
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Vector, per se
435456, 435464, 536 231, C12N 1500, C12N 112, C07H 2102
Patent
active
060805757
ABSTRACT:
The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B) c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases.
REFERENCES:
Specific Chemoimmunotherapy, pp. 81-85.
M. Schmitt, et al., "Tumor-associated Proteases", Fibrinolysis, vol. 6, Suppl. 4, pp. 3-26 (1992).
D.W. Cottam et al., "Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (Review)", International Journal of Oncology, vol. 2, pp. 861-872 (1993).
Tryggvason et al. "Type IV collagenases in invasive tumors", Breast Cancer Research and Treatment, vol. 24, pp. 209-218 (1993).
Leto et al., "Cathespin D in the Malignant Progression of Neoplastic Diseases (Review)," Anticancer Research, vol. 12, pp. 235-240 (1992).
D.A. Hart, "Dysregulation of Plasminogen Activators in Cancer--Potential Role in Invasion, Metastasis and as a Prognostic Indicator", Fibrinolysis, vol. 6, Suppl. 1, pp. 11-15 (1992).
Albini, et al., "Tumor Cell Invasion Inhibited by TIMP-2", Reports, vol. 83, No. 11, pp. 775-779 (Jun. 5, 1991).
Hocman, "Chemoprevention of Cancer: Protease Inhibitors", Minireview, pp. 1365-1375 (1991).
Walter Troll, Ph.D., et al., "Protease Inhibitors as Anticarcinogens", JNCI, vol. 73, No. 6, pp. 1245-1250 (Dec. 1984).
J.M. Ray, et al., "The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis", Eur Respir J, vol. 7, pp. 2062-2072 (1994).
Koop, et al., "Overexpression of Metalloproteinase Inhibitor in B16F10 Cells Does Not Affect Extravasation but Reduces Tumor Growth", Cancer Research, vol. 54, pp. 4791-4797 (Sep. 1, 1994).
Chirivi, et al., "Inhibition of the Metastatic Spread and Growth of B16-BL6 Murine Melanoma by a Synthetic Matrix Metalloproteinase Inhibitor", Int. J. Cancer, vol. 58, pp. 460-464 (1994).
Denhardt, et al., "Tissue Inhibitor of Metalloproteinases (TIMP, aka EPA): Structure, Control of Expression and Biological Functions", Pharmac. Ther., vol. 59, pp. 329-341 (1993).
Melchiori, et al., "Inhibition of Tumor Cell Invasion by a Highly Conserved Peptide Sequence from the Matrix Metalloproteinase Enzyme Prosegment", Cancer Research, vol. 52, pp. 2353-2356 (Apr. 15, 1992).
Panchal, et al., "Tumor protease-activated, pore-forming toxins from a combinatorial library", Nature Biotechnology, vol. 14, pp. 852-856 (Jul. 1996).
McDonald, et al., "A Brief History of the Study of Mammalian Exopeptidases", Mammalian Proteases, vol. 2, pp. 5-19 (1986).
Pappot, et al., The plasminogen activation system and its role in lung cancer. A review., "Lung Cancer", vol. 12, pp. 1-12 (1995).
Monsky, et al., "Proteases of cell adhesion proteins in cancer", Cancer Biology, vol. 4, pp. 251-258 (1993).
Rochefort, et al., "Proteases lysosomiales et invasion tumorale", medecine/sciences, vol. 7, pp. 30-36 (1991).
Kao, et al., "Collagenases in Human Breast Carcinoma Cell Lines", Cancer Researc, vol. 46, pp. 1349-1354 (Mar. 1986).
Fridman, et al., "Activation of Progelatinase B (MMP-9) by Gelatinase A (MMP-2)", Cancer Research, vol. 55, pp. 2548-2555 (Jun. 15, 1995).
Monsky, et al., "A Potential Marker Protease of Invasiveness, Seprase, Is Localized on Invadopodia of Human Malignant Melanoma Cells", Cancer Research, vol. 54, pp. 5702-5710 (Nov. 1, 1994).
Kao, et al., "Elastases in Human Breast Carcinoma Cell Lines", Cancer Research, vol. 46, pp. 1355-1358 (Mar. 1986).
Lundwall, "Characterization of the gene for Prostate-specific antigen, a human glandular kallikrein", Biochemical and Biophysical Research Communications, vol. 161, No. 3, pp. 1151-1159 (1989).
Riegman, et al., "Characterization of the Prostate-Specific Antigen Gene: A Novel Human Kallikrein-Like Gene", Biochemical and Biophysical Research Communications, vol. 159, No. 1 (1989).
Miszczuk-Jamska, et al., Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines; CFPAC-1 and CAPAN-1, FEBS, vol. 294, No. 3, pp. 175-178 (1991).
Prockop, et al., "Collagens: Molecular Biology, Diseases, and Potentials for Therapy", Annu. Rev. Biochem., vol. 64, pp. 403-434 (1995).
Ichijo, et al., "Molecular Cloning and Characterization of Ficolin, a Multimeric Protein with Fibrinogen- and Collagen-like Domains", The Journal of Biological Chemistry, vol. 268, No. 19, pp. 14505-14513 (1993).
Wetzels, et al., "Distribution Patterns of Type VII Collagen in Normal and Malignant Human Tissues", American Journal of Pathology, vol. 139, No. 2, pp. 451-459 (Aug. 1991).
Bellahcene, et al., "Expression of Bone Sialoprotein, a Bone Matrix Protein, in Human Breast Cancer", Cancer Research, vol. 54, pp. 2823-2826 (Jun. 1, 1994).
von der Mark, et al., "Laminin and its receptor", Biochimica et Biophysica Acta, vol. 823, pp. 147-160 (1985).
Hunt, "The Role of Laminin in Cancer Invasion and Metastasis", Expl Cell Biol, vol. 57, pp. 165-176 (1989).
Schmidtchen, et al., "Hydrophobic Interaction Chromatography of Fibroblast Proteoglycans", Biomedical Chromatography, vol. 7, pp. 48-55 (1993).
Barclay, et al., "Protein Superfamilies and Cell Surface Molecules", The Leucocyte Antigen Facts Book, pp. 38-87 (1993).
Pigott, et al., "The Adhesion Molecule Facts Book", pp. 1-21 (1993).
Ayad, et al., "The Extracellular Matrix Facts Book", pp. 8-16 (1994).
Oyama, et al., "Qualitative and Quantitative Changes of Human Tenascin Expression in Transformed Lung Fibroblast and Lung Tumor Tissues: Comparison with Fibronectin", Cancer Research, vol. 51, pp. 4876-4881 (Sep. 15, 1991).
Herlyn, et al., "Characterization of Tenascin Secreted by Human Melanoma Cells", Cancer Research, vol. 51, (Sep. 15, 1991).
Olson, et al., "bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out", Genes & Development, vol. 8, pp. 1-8 (1994).
Arceci, et al., "Mouse GATA-4: a Retinoic Acid-Inducible GATA-Binding Transcription Factor Expressed in Endodermally Derived Tissues and Heart", Molecular and Cellular Biology, vol. 13, No. 4, pp. 2235-2246 (Apr. 1993).
IP, et al., "The GATA-4 Transcription Factor Transactivates the Cardiac Muscle-Specific Troponin C Promoter-Enhancer in Nonmuscle Cells", Molecular and Cellular Biology, vol. 14, No. 11, (Nov. 1994).
Yu, et al., "Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors", Genes & Development, vol. 6, pp. 1783-1798 (1992).
Weintraub, et al., "MyoD binds cooperatively to two sites in a target enhancer sequence: Occupancy of two sites is required for activation", Proc. Natl. Acad. Sci. USA, vol. 87, pp. 5623-5627 (Aug. 1990).
Molkentin, et al., "Transcription Factor GATA-4 Regulates Cardiac Muscle-Specific Expression of the .alpha.-Myosin Heavy-Chain Gene", Molecular and Cellular Biology, vol. 14, No. 7, pp. 4947-4957 (Jul. 1994).
Dougherty, et al., "Gene Therapy-based Approaches to the Treatment of Cancer: Development of Targetable Retroviral Vectors", Transfus, Sci., vol. 17, No. 1, pp. 121-128 (1996).
Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA, vol. 85, pp. 5879-5883 (Aug. 1988).
McCafferty, et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, vol. 348, pp. 552-554 (Dec. 1990).
Jespers, et al., "Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of
Heidtmann Hans Heinrich
Mueller Rolf
Sedlacek Hans-Harald
Hoechst Aktiengesellschaft AG
Hutzell Paula K.
Sun-Hoffman Lin
LandOfFree
Nucleic acid construct for expressing active substances which ca does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid construct for expressing active substances which ca, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid construct for expressing active substances which ca will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1783418